## Amendments to the Abstract

Please amend the Abstract as follows:

~~A discovery process beginning with an *in vivo* screening of proteins, peptides, natural products, classical medicinal compound or other substances. The administration of compounds to the animal can be either direct or indirect, such as by the administration and expression of cDNA-containing plasmids. Since the discovery process of the invention is based on a non-preconceived hypothesis and whole organism multi-organ analysis, a compound can be selected for testing in the absence of any biological selection criteria. The resulting organism-wide pattern of the gene expression changes in the transcriptome provides an overview of the activities at the molecular and organism-wide levels. The discovery process of the invention then integrates *in vivo* profiling and internal and external genomic databases to elucidate the function of unknown proteins, typically within few months.~~ The ~~invention~~ further disclosure relates to ~~medical uses~~ methods of manufacture of medicaments comprising ~~of~~ fibroblast growth factor 23 (FGF-23), a fragment of FGF-23, a bioactive polypeptide having a percentage of identity of at least 95% with the amino acid sequence of any one of these polypeptides, and/or bioactive variants of any one of these polypeptides, ~~FGF-23 fragments, FGF-23 C-terminal polypeptides, FGF-23 homologs and/or FGF-23 variants~~ for use in treatment of diseases associated with deregulated angiogenesis. Such diseases include chronic or acute renal diseases, arteriosclerosis, atherosclerosis, psoriasis, endometriosis, diabetes, chronic asthma and cancer.